Should you wish to receive an email alert when this page is updated with a new press release, please register with our Alert Service.



Date Title
29/11/2007 Cosmo’s Rifamycin SV MMX™ meets clinical endpoints in Phase II trial for infectious diarrhoea
20/11/2007 MEZAVANT XL™ launched in the UK
11/10/2007 Cosmo announces Licensing Agreement with Ferring for Budesonide MMX™
05/10/2007 Digestive & Liver Disease journal published an article on Low Molecular Weight Heparin MMX
05/10/2007 Market Making Agreement
25/07/2007 Cosmo Pharmaceuticals reports HY results
04/07/2007 Cosmo Pharmaceuticals reports positive preliminary Phase II/III data with Rifamycin MMX™ in Infectious Diarrhoea
21/06/2007 Disclosure of shareholdings
06/06/2007 Cosmo improves Licensing Agreement with Giuliani for LIALDA™ MMX™
20/03/2007 Cosmo Pharmaceuticals: Market Launch of LIALDA
15/03/2007 Cosmo Pharmaceuticals S.p.A. IPO over-allotment option fully exercised
08/03/2007 Offer price for Cosmo Pharmaceuticals S.p.A.
26/02/2007 Cosmo Pharmaceuticals S.p.A. launches IPO on the SWX Swiss Exchange
12/02/2007 Cosmo Pharmaceuticals S.p.A. seeks a listing on the SWX Swiss Exchange
17/01/2007 LIALDA TM MMX treatment for ulcerative colitis gets FDA approval


Back to top